Combinatorial chemistry technology: method – library – apparatus – Method of screening a library – By measuring the ability to specifically bind a target...
Reexamination Certificate
2011-04-26
2011-04-26
Goddard, Laura B (Department: 1642)
Combinatorial chemistry technology: method, library, apparatus
Method of screening a library
By measuring the ability to specifically bind a target...
Reexamination Certificate
active
07932212
ABSTRACT:
The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
REFERENCES:
patent: 5698178 (1997-12-01), Goldenberg et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6930089 (2005-08-01), Carmeliet
patent: 7105168 (2006-09-01), Carmeliet et al.
patent: 7226908 (2007-06-01), Carmeliet et al.
patent: 7307060 (2007-12-01), Compernolle et al.
patent: 7357929 (2008-04-01), Carmeliet et al.
patent: 7482004 (2009-01-01), Carmeliet et al.
patent: 2003/0180286 (2003-09-01), Carmeliet et al.
patent: 2007/0027100 (2007-02-01), Carmeliet et al.
patent: 2007/0172423 (2007-07-01), Li et al.
patent: 2007/0249539 (2007-10-01), Carmeliet et al.
patent: 99/24056 (1999-05-01), None
patent: 0185796 (2001-11-01), None
patent: WO 02/46213 (2002-06-01), None
Ahmad et al., “Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia”, Circ. Res. 95:884-891 (2004).
Hornig et al., “Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids”, Lab. Invest. 80(4):443-54 (2000).
Supplemental European Search Report for 06826058.7, filed Jun. 16, 2006, date of mailing Oct. 7, 2009.
Donnini et al., “Expression and Localization of Placenta Growth Factor and PlGF Receptors in Human Meningiomas”, J. Pathol. 189:66-71 (1999).
Fischer et al., “Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels”, Cell 131:463-475 (2007).
Selvaraj et al., “Mechanism of Monocyte Activation and Expression of Proinflammatory Cytochemokines by Placenta Growth Factor”, Blood 2003, vol. 102, No. 4, pp. 1515-1524.
Semenza, Gregg L., “A new Weapon for Attacking Tumor Blood Vessels”, N. Engl. J. Med. May 8, 2008;358 (19):2066-7.
Chang Chien-Hsing
Goldenberg David M.
Taylor Alice P.
Center for Molecular Medicine & Immunology
Goddard Laura B
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Inhibition of placenta growth factor (PlGF) mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of placenta growth factor (PlGF) mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of placenta growth factor (PlGF) mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699248